azacitidine has been researched along with belinostat in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, DE; Dos Santos, JL; Lopes, JR | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Brown, R; Finn, P; Plumb, JA; Steele, N | 1 |
| Brown, R; Dai, W; Plumb, JA; Rizzo, S; Siddiq, A; Steele, NL; van der Zee, A; Walley, AJ; Wilhelm-Benartzi, CS; Zeller, C | 1 |
| Bennett, M; Fulton, N; Godley, LA; Green, M; Halpern, A; Karrison, T; Koval, G; Larson, RA; Madzo, J; Malnassy, G; Mattison, RJ; Odenike, O; Ratain, MJ; Stock, W; Yee, KW | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 review(s) available for azacitidine and belinostat
| Article | Year |
|---|---|
HIV latency reversal agents: A potential path for functional cure?
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Molecular Structure; Virus Latency | 2021 |
1 trial(s) available for azacitidine and belinostat
| Article | Year |
|---|---|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Gene Expression; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Sulfonamides; Up-Regulation | 2015 |
4 other study(ies) available for azacitidine and belinostat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Hydroxamic Acids; Melanoma-Specific Antigens; Mice; Mice, Nude; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cisplatin; Collagen Type I; Collagen Type I, alpha 1 Chain; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Midkine; MutL Protein Homolog 1; Nerve Growth Factors; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |